MLYS
NASDAQMineralys Therapeutics Inc.
News25/Ratings10
News · 26 weeks102+7%
2025-12-282026-06-21
Mix4790d
- SEC Filings24(51%)
- Insider12(26%)
- Other7(15%)
- Earnings2(4%)
- Analyst1(2%)
- Offering1(2%)
Latest news
25 items- INSIDERChief Medical Officer Rodman David Malcom sold $350,087 worth of shares (14,474 units at $24.19) as part of a pre-agreed trading plan and exercised 8,126 shares at a strike of $12.55, decreasing direct ownership by 10% to 57,095 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERDirector Karydas Daphne exercised 3,000 shares at a strike of $12.02 and sold $75,000 worth of shares (3,000 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure – RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldost
- INSIDERChief Medical Officer Rodman David Malcom exercised 8,519 shares at a strike of $4.88 and sold $206,151 worth of shares (8,519 units at $24.20) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceRADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026. Goldman Sachs 47th Annual Global Healthcare ConferenceDate:Tuesday, June 9, 2026Time:2:40pm ETFormat:Fireside ChatWebcast Link A live webcast of this fireside chat can also be accessed on the "News & Events" page
- SECMineralys Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- SECSEC Form 424B5 filed by Mineralys Therapeutics Inc.424B5 - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- SECMineralys Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- PRMineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockRADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the of
- PRMineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met – – $500 million committed under senior secured term loan facility from funds managed by Pharmakon Advisors, LP – – Priced $150 million Common Stock Offering – RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced the repurchase of all
- PRMineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio – – Lorundrostat demonstrated a favorable safety profile in participants with and without chronic kidney disease over 12 weeks – RADNOR, Pa., May 30, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstr
- PRMineralys Therapeutics to Participate in the Jefferies Global Healthcare ConferenceRADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Jefferies 2026 Global Healthcare Conference being held in New York on June 2-4, 2026. Jefferies Global Healthcare ConferenceDate:Wednesday, June 3, 2026Time:7:35am EDTFormatCorporate PresentationWebcast Link A live webcast of this presentation can also be accessed on the "News & Events" page in the Investor Relati
- SECMineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
- INSIDERChief Medical Officer Rodman David Malcom exercised 417 shares at a strike of $15.44 and sold $11,488 worth of shares (417 units at $27.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Medical Officer Rodman David Malcom exercised 16,226 shares at a strike of $8.45 and sold $652,638 worth of shares (22,575 units at $28.91) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 63,443 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 10-Q filed by Mineralys Therapeutics Inc.10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)
MLYS FAQ
6 questionsWhere does MLYS stock trade?
Mineralys Therapeutics Inc. (MLYS) is listed on NASDAQ.What sector and industry is MLYS in?
Mineralys Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mineralys Therapeutics Inc. go public?
Mineralys Therapeutics Inc. (MLYS) completed its IPO in 2023.What are analysts saying about MLYS?
Mineralys Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-04-27. Recent price targets range from $1500.00 to $3900.00.What companies are similar to MLYS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MLYS side-by-side with any of them on Quantisnow.How can I track MLYS on Quantisnow?
Quantisnow aggregates Mineralys Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLYS to receive live email and push alerts on every new disclosure.